- Earlier this week, the Centers for Medicare & Medicaid Services finalized a 2.48% average increase in 2027 Medicare Advantage payment rates, an upgrade from its January proposal that directly affects private insurers such as Humana.
- Separately, Humana’s 2025 Impact Report detailed efforts to simplify coverage, expand access for Medicare and Medicaid members, and reduce hospital and emergency department use through value-based care.
- Next, we’ll examine how the higher 2027 Medicare Advantage payment update could influence Humana’s existing investment narrative and risk profile.
Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Humana Investment Narrative Recap
To own Humana, you need to believe Medicare Advantage and value based care can still produce acceptable margins despite volatile medical costs and regulatory scrutiny. The higher 2.48% 2027 Medicare Advantage rate update supports the near term margin recovery story, but it does not remove key risks around Stars ratings, coding changes and cost trends, which remain central to the thesis and could still weigh on earnings if they break against Humana.
Humana’s 2025 Impact Report is especially relevant here, because it shows concrete progress in value based care, with lower inpatient admissions and emergency department use among Medicare Advantage members. If that operational execution continues, it could help offset pressure from medical cost trends and MACRA V28 coding changes, while making better use of the improved 2027 reimbursement backdrop.
Yet even with improved 2027 rates, investors should be aware that uncertainties around CMS Stars litigation and future reimbursement policy could still...
Read the full narrative on Humana (it's free!)
Humana's narrative projects $184.4 billion revenue and $3.1 billion earnings by 2029.
Uncover how Humana's forecasts yield a $212.17 fair value, a 8% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$203.9 billion and earnings US$4.2 billion by 2029, so if you are weighing that view against ongoing concerns about Stars ratings and reimbursement risk, this week’s payment news may eventually tilt those narratives in different directions.
Explore 10 other fair value estimates on Humana - why the stock might be worth 26% less than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Humana research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.
Interested In Other Possibilities?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com